Search research articles
Contact Us
Filters
Showing results (131-140 of 185) with videos related to
Page
of 19
Sort By:
Future Oncology (London, England)
|
December 25, 2019
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma
Jason J Luke, Paolo A Ascierto, Matteo S Carlino, et al.
Pigment Cell & Melanoma Research
|
August 13, 2014
Biology of advanced uveal melanoma and next steps for clinical therapeutics
Jason J Luke, Pierre L Triozzi, Kyle C McKenna, et al.
Journal of Translational Medicine
|
July 24, 2019
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)
Paolo A Ascierto, Sanjiv S Agarwala, Gerardo Botti, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 5, 2024
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinoma
Jason J Luke, Georgina V Long, Caroline Robert, et al.
Cancer
|
January 29, 2019
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma
Patrick A Ott, Anna C Pavlick, Douglas B Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 13, 2024
Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Jason J Luke, Karen Gelmon, Lillian L Siu, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 7, 2024
Radiomic analysis of patient and inter-organ heterogeneity in response to immunotherapies and BRAF targeted therapy in metastatic melanoma
Alexandra Tompkins, Zane N Gray, Rebekah E Dadey, et al.
Nature Medicine
|
October 13, 2022
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial
Richard D Carvajal, Marcus O Butler, Alexander N Shoushtari, et al.
Journal of Translational Medicine
|
July 23, 2018
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)
Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, et al.
Journal for Immunotherapy of Cancer
|
February 20, 2021
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
Jason J Luke, Fabrice Barlesi, Ki Chung, et al.
Page
of 19
Search research articles
Search
Showing results (131-140 of 185) with videos related to
Sort By:
Page
of 19
Future Oncology (London, England)
|
December 25, 2019
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma
Jason J Luke, Paolo A Ascierto, Matteo S Carlino, et al.
Pigment Cell & Melanoma Research
|
August 13, 2014
Biology of advanced uveal melanoma and next steps for clinical therapeutics
Jason J Luke, Pierre L Triozzi, Kyle C McKenna, et al.
Journal of Translational Medicine
|
July 24, 2019
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy)
Paolo A Ascierto, Sanjiv S Agarwala, Gerardo Botti, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 5, 2024
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinoma
Jason J Luke, Georgina V Long, Caroline Robert, et al.
Cancer
|
January 29, 2019
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma
Patrick A Ott, Anna C Pavlick, Douglas B Johnson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 13, 2024
Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies
Jason J Luke, Karen Gelmon, Lillian L Siu, et al.
Medrxiv : the Preprint Server for Health Sciences
|
May 7, 2024
Radiomic analysis of patient and inter-organ heterogeneity in response to immunotherapies and BRAF targeted therapy in metastatic melanoma
Alexandra Tompkins, Zane N Gray, Rebekah E Dadey, et al.
Nature Medicine
|
October 13, 2022
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial
Richard D Carvajal, Marcus O Butler, Alexander N Shoushtari, et al.
Journal of Translational Medicine
|
July 23, 2018
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy)
Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, et al.
Journal for Immunotherapy of Cancer
|
February 20, 2021
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
Jason J Luke, Fabrice Barlesi, Ki Chung, et al.
Page
of 19